Ann: Intention to launch Share Purchase Plan, page-69

The key word is 'these'. We are funded to the end of THESE current trials - ending around July 2024 with results following.

There are lots of possible ways forward but narrowing to three outcomes at the end of these trails, the results will have us:

1. fast track approval. The assumption would then be; an offer to buy equity in ANP from a big Pharma and work with them (fully funding us), or be taken over by them.

The company might also decide to go it alone (doubt given the funds required to commercialise) but at this point a CR would be required but at a high SP.

2. further testing and results required - CR or partnering would be required

3. results show the drug fails


Here is the info in the SPP announcement:

The new funds will allow us to continue the development of our clinical programs, in particular funding the ongoing international Phase IIb Clinical Trial program for ATL1102 in Duchenne muscular dystrophy, as well as for ongoing working capital.